Take a deep dive into the opportunities and limitations of new trial methodologies and their implementation - specifically, registry trials and teletrials.
Both of these trial types show a lot of promise, with early data pointing to their potential for increasing trial recruitment and participation for consumers, especially in remote or rural areas. They also reduce administrative burden on trial units and allow clinicians and researchers to learn valuable lessons from as many patients as possible. However, there's more to be done to see them more widely adopted in clinical settings.
Professor Peter Gibbs and clinical trial experts will look at how registry trials and teletrials are placed in the context of the cancer clinical trial landscape, share important case studies, and discuss how to forge a path towards greater clinical uptake of these trials in the future.
The webinar will conclude with a panel discussion and audience Q&A.
Registry Trials as a Novel Trial Platform
Dr Lucy Gately is a medical oncologist and clinical research fellow at WEHI. She leads a program of research in brain cancer and has an interest in real world data collection and registry trials.
Registry Trial Perspectives from Study Site Staff & Take Home Lessons
Shehara is a medical oncologist and clinical researcher with current appointments at Western Health, Cabrini Health and the Walter & Eliza Hall Institute of Medical Research (WEHI). She obtained a Master of Cancer Sciences whilst undertaking a clinical and research fellowship specialising in cancers of the gastrointestinal tract at BC Cancer in Vancouver, Canada. She is involved in the full spectrum of clinical trials, from early phase to investigator-initiated and registry-based clinical trials.
Teletrials and Adapting the Model
Pascale Dettwiller is the liaison officer for the Australian Teletrial Program in South Australia. She holds a Doctor of Pharmacy from the School of Pharmacy, Joseph Fourier University, Grenoble (France) and several Bachelor and Diploma awards in Teaching, Business (MBA), Certificate in Geriatrics Pharmacy (USA). She has held Senior Academic and Research positions in Australia, and Senior Clinical Pharmacist positions at governmental and non-governmental health organisations in New Caledonia, Tasmania, Victoria, Northern Territory and now South Australia. She loves teaching and sharing knowledge to advance the care we provide to our regional patients and the community as a whole.
Professor Peter Gibbs is a medical oncologist and head of division at the WEHI. His lab leads lead national and international cancer registries that capture comprehensive patient, tumour, treatment and outcome data for all major solid cancers. This data is used to enable audit and research, including supporting the novel concept of registry based clinical trials in oncology collection and translational research by combining data and tissue based research.
At the age of 41, Scott Duncan was diagnosed with Stage III colon cancer in September 2022. Having had no prior health issues, the news of a potentially life-threatening illness came as quite a shock. Scott underwent surgery at Epworth Richmond to remove the tumor and was fitted with a loop ileostomy. Scott transferred his ongoing cancer treatment to Peter Mac following his surgery and is currently under the care of Dr. Jeanie Tie where Jeanie invited Scott to participate in the Dynamic III Research Trial (Circulating Tumor DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer).
Having now finished his treatment, Scott returned to work at the beginning of 2023 as an Acting Principal in a Melbourne primary school. He has also returned to the gym and is excited to be taking an overseas holiday later this year.
